Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

Cancer Immunology, Immunotherapy

Volumn 59, Issue 6, 2010, Pages 863-873

  Dangoor, Adam ^a   Lorigan, Paul ^b   Keilholz, Ulrich ^c   Schadendorf, Dirk ^d   Harris, Adrian ^e   Ottensmeier, Christian ^f   Smyth, John ^g   Hoffmann, Klaus ^h   Anderson, Richard ⁱ   Cripps, Martin ⁱ   Schneider, Joerg ^i,j   Hawkins, Robert ^b  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e CHURCHILL HOSPITAL   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g Edinburgh Cancer Research Centre   (United Kingdom)

^h RUHR UNIVERSITY BOCHUM   (Germany)

ⁱ OXFORD BIOMEDICA UK LTD   (United Kingdom)

^j Emergent Biosolutions   (United Kingdom)

more..

Author keywords

Melanoma; Polyepitope; Primeboost; Therapeutic vaccine

Indexed keywords

DNA VACCINE; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; MELAN A; MELANOMA ANTIGEN; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PLASMID DNA; TETRAMER; VIRUS VECTOR; CANCER VACCINE; MART1 ANTIGEN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ARTICLE; CANCER STAGING; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; LOW DRUG DOSE; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; SURVIVAL TIME; SYNCOPE; VACCINATION; VIRUS RECOMBINANT; GENETICS; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; SECRETION; SURVIVAL; VACCINIA VIRUS;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; SURVIVAL ANALYSIS; VACCINIA VIRUS;

EID: 77953098156     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0811-7     Document Type: Article

References (31)

1. M King D Spooner DC Rowlands 2001 Spontaneous regression of metastatic malignant melanoma of the parotid gland and neck lymph nodes: A case report and a review of the literature Clin Oncol (R Coll Radiol) 13 466 469 1:STN:280:DC%2BD38%2FpsVyrug%3D%3D
2. K Itoh CD Platsoucas CM Balch 1988 Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor J Exp Med 168 1419 1441 10.1084/jem.168.4.1419 1:CAS:528:DyaL1cXmtV2mtbk%3D 3262710 (Pubitemid 18264875)
3. DJ Schwartzentruber SL Topalian M Mancini SA Rosenberg 1991 Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation J Immunol 146 3674 3681 1:CAS:528: DyaK3MXltFantrk%3D 1902860
4. T Talebi JS Weber 2003 Peptide vaccine trials for melanoma: Preclinical background and clinical results Semin Cancer Biol 13 431 438 10.1016/j.semcancer.2003.09.007 1:CAS:528:DC%2BD2cXks1yksQ%3D%3D 15001162 (Pubitemid 38156135)
5. L Pilla R Valenti A Marrari R Patuzzo M Santinami, et al. 2006 Vaccination: role in metastatic melanoma Expert Rev Anticancer Ther 6 1305 1318 10.1586/14737140.6.8.1305 1:CAS:528:DC%2BD28XpslGhsLo%3D 16925496 (Pubitemid 44304698)
6. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 909 915 10.1038/nm1100 1:CAS:528: DC%2BD2cXntFSktL0%3D 15340416 (Pubitemid 39273730)
7. SA Rosenberg JC Yang RM Sherry P Hwu SL Topalian, et al. 2003 Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen Hum Gene Ther 14 709 714 10.1089/ 104303403765255110 1:CAS:528:DC%2BD3sXjvVyns7s%3D 12804135 (Pubitemid 36623509)
8. PL Triozzi W Aldrich KO Allen RR Carlisle AF LoBuglio, et al. 2005 Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse J Immunother 28 382 388 10.1097/01.cji.0000162779. 88687.4c 1:CAS:528:DC%2BD2MXlvVCis7s%3D 16000957
9. J Zhu J Martinez X Huang Y Yang 2007 Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta Blood 109 619 625 10.1182/blood-2006-06-027136 1:CAS:528:DC%2BD2sXivVyrsrk%3D 16973959 (Pubitemid 46105962)
10. CL Smith PR Dunbar F Mirza MJ Palmowski D Shepherd, et al. 2005 Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence Int J Cancer 113 259 266 10.1002/ijc.20569 1:CAS:528:DC%2BD2cXhtFajtLbL 15386406 (Pubitemid 39628316)
11. SJ McConkey WH Reece VS Moorthy D Webster S Dunachie, et al. 2003 Enhanced T cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans Nat Med 9 729 735 10.1038/nm881 1:CAS:528:DC%2BD3sXktFOnu7Y%3D 12766765 (Pubitemid 36749222)
12. MJ Palmowski EM Choi IF Hermans SC Gilbert JL Chen, et al. 2002 Competition between CTL narrows the immune response induced by prime-boost vaccination protocols J Immunol 168 4391 4398 1:CAS:528:DC%2BD38Xjt12jsbc%3D 11970981
13. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
14. Y Xu V Theobald C Sung K DePalma L Atwater, et al. 2008 Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients J Transl Med 6 61 10.1186/1479-5876-6-61 1:CAS:528: DC%2BD1cXht1emsLrP 18945350
15. CM Balch AC Buzaid SJ Soong MB Atkins N Cascinelli, et al. 2001 Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J Clin Oncol 19 3635 3648 1:STN:280:DC%2BD3MvlvV2ktQ%3D%3D 11504745
16. CM Balch SJ Soong JE Gershenwald JF Thompson DS Reintgen, et al. 2001 Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol 19 3622 3634 1:STN:280:DC%2BD3MvlvV2ktA%3D%3D 11504744
17. AY Bedikian M Millward H Pehamberger R Conry M Gore, et al. 2006 Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group J Clin Oncol 24 4738 4745 10.1200/JCO.2006.06.0483 1:CAS:528:DC%2BD28XhtFynsr3L 16966688 Epub 2006 Sep 4711 (Pubitemid 46630937)
18. U Vaishampayan J Abrams D Darrah V Jones MS Mitchell 2002 Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha Clin Cancer Res 8 3696 3701 1:CAS:528:DC%2BD38XpslCjtrs%3D 12473578
19. A Ribas LH Camacho G Lopez-Berestein D Pavlov CA Bulanhagui, et al. 2005 Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206 J Clin Oncol 23 8968 8977 10.1200/JCO.2005.01.109 1:CAS:528: DC%2BD28XktVCnsg%3D%3D 16204013 Epub 2005 Oct 8963 (Pubitemid 46217464)
20. A Hoos G Parmiani K Hege M Sznol H Loibner, et al. 2007 A clinical development paradigm for cancer vaccines and related biologics J Immunother 30 1 15 10.1097/01.cji.0000211341.88835.ae 17198079 (Pubitemid 46052199)
21. J Schneider SC Gilbert TJ Blanchard T Hanke KJ Robson, et al. 1998 Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara Nat Med 4 397 402 10.1038/nm0498-397 1:CAS:528:DyaK1cXisVeltrc%3D 9546783 (Pubitemid 28212753)
22. R Harrop N Connolly I Redchenko J Valle M Saunders, et al. 2006 Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial Clin Cancer Res 12 3416 3424 10.1158/1078-0432.CCR-05-2732 1:CAS:528:DC%2BD28XltFyis7c%3D 16740766
23. IF Luescher P Romero D Kuznetsov D Rimoldi P Coulie, et al. 1996 HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44 J Biol Chem 271 12463 12471 10.1074/jbc.271.21.12463 1:CAS:528:DyaK28XjtFantrw%3D 8647853 (Pubitemid 26160917)
24. E Harrer M Bauerle B Ferstl P Chaplin B Petzold, et al. 2005 Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: Safety, immunogenicity and influence on viral load during treatment interruption Antivir Ther 10 285 300 1:CAS:528:DC%2BD2MXkvFyqsr8%3D 15865223
25. F Wang E Bade C Kuniyoshi L Spears G Jeffery, et al. 1999 Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma Clin Cancer Res 5 2756 2765 1:CAS:528:DyaK1MXntlGltb0%3D 10537339
26. AC Peterson H Harlin TF Gajewski 2003 Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T cell responses in advanced melanoma J Clin Oncol 21 2342 2348 10.1200/JCO.2003.12.144 1:CAS:528: DC%2BD2cXpsVKjs7g%3D 12805336 (Pubitemid 46628465)
27. H Benlalam V Vignard A Khammari A Bonnin Y Godet, et al. 2007 Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients Cancer Immunol Immunother 56 515 526 10.1007/s00262-006-0204-0 1:CAS:528:DC%2BD2sXht1yhsb4%3D 16874485 (Pubitemid 46204537)
28. A Mackensen N Meidenbauer S Vogl M Laumer J Berger, et al. 2006 Phase I study of adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma J Clin Oncol 24 5060 5069 10.1200/JCO.2006.07.1100 1:CAS:528:DC%2BD28Xht1Gnur3O 17075125 (Pubitemid 46631410)
29. A Luckay MK Sidhu R Kjeken S Megati SY Chong, et al. 2007 Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques J Virol 81 5257 5269 10.1128/JVI.00055-07 1:CAS:528:DC%2BD2sXls1GrsbY%3D 17329330 (Pubitemid 46744435)
30. V Appay V Voelter N Rufer S Reynard C Jandus, et al. 2007 Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma J Immunother 30 240 250 10.1097/01.cji.0000211332.68643.98 1:CAS:528:DC%2BD2sXjsVKntbw%3D 17471171 (Pubitemid 46667804)
31. LA Emens EM Jaffee 2005 Leveraging the activity of tumor vaccines with cytotoxic chemotherapy Cancer Res 65 8059 8064 10.1158/0008-5472.CAN-05-1797 1:CAS:528:DC%2BD2MXhtVShsb3L 16166275 (Pubitemid 41330564)